Law Firms Can Get It Wrong When They Threaten Corporations Like; Capricor; We Continue To Reiterate Strong Buy $34 - $46 Near Term

What the Law Firm Asserts:

• The firm claims there was a maleficent (wrongful or misleading) event on May 5, 2025, related to Capricor’s public communications about their mid-cycle FDA review for the BLA (Biologics License Application) for deramocel.
• They specifically highlight the subsequent stock drop after Capricor’s press release telling the FDA “Confirmed its intent to hold an advisory committee meeting” for the drug.
• They claim further damage after the June 20, 2025, STAT publication reported that the new FDA head canceled the advisory meeting due to efficacy and safety uncertainty.

 

Breaking Down Their Claims—Skeptically and Factually

 

1. 

Did Capricor’s May 5 Press Release Mislead Investors?

• Nature of the Release:

According to the law firm’s summary, Capricor simply disclosed that the FDA “confirmed its intent to hold an advisory committee meeting.” This is a standard, factual update in the BLA process.

• Is This Materially Misleading?

Unless Capricor knew or had reason to know that the meeting would be canceled, or unless they omitted negative information, there is nothing inherently misleading about reporting the FDA’s then-current position.

§   

• • Standard Practice: Companies are required by the SEC to promptly and accurately update the market on regulatory milestones. Announcing an FDA intent to hold a meeting is both typical and prudent.
• Stock Drop Reaction:

The market’s negative reaction is not in itself evidence of wrongdoing. Volatility is common in biotech, especially around regulatory events. The drop could reflect investor anxiety about regulatory hurdles, not necessarily any misconduct by Capricor.

 

2. 

Was There a Material Omission or Falsehood?

• Key Legal Standard:

For a securities class action to succeed, the firm must prove Capricor made a materially false statement or omitted material negative information they possessed.

• Timeline:
  • On May 5, Capricor reported the FDA’s confirmed intent—which, at the time, appears to have been accurate.
  • The June 20 news (about the canceled meeting) happened after this, due to new leadership at FDA and possibly evolving internal agency concerns.
• No Evidence of Prior Knowledge:

Unless there is evidence Capricor already knew about the potential cancellation or concerns, there is no basis to say their earlier statement was false or misleading.

 

3

Biotech Volatility & Regulatory Risk

• Regulatory Pathway is Uncertain by Nature:

It is not unusual for the FDA to change its process or for meetings to be scheduled and later canceled. This is part of the risk inherent in biotech investment.

• Stock Price Fluctuations:

The market reacting to real-time news is not actionable unless there’s fraud. Both drops (May 6 and June 20) reflect real-time, public information.

 

Counter-Points to the Law Firm’s Claims

1. No Concrete Evidence of Malfeasance:

The screenshots show no hard evidence that Capricor misrepresented facts or omitted critical negative information prior to May 5.

1. Proper Disclosure:

Capricor appears to have promptly disclosed all major regulatory updates as required. Reporting the FDA’s current intent is what’s expected.

1. Retrospective Blame is Not Proof:

It is easy for law firms to assert wrongdoing after a stock price drop, but post-hoc market declines are not, by themselves, evidence of fraud or negligence.

1. Biotech Litigation is Often Opportunistic:

These class action investigations often arise after any significant biotech stock drop, as plaintiff law firms' “fish” for potential clients, hoping to find internal documents or whistleblowers. The mere announcement of an “investigation” is not proof of merit.

 

Taking a Journey With a Few Conclusions & Thoughts

 

In summary: Based on what’s visible in the screenshots attached and the public records:

• The law firm’s assertion of a “maleficent” event on May 5 appears unsupported by the facts as publicly shown.
• Capricor’s press releases and regulatory disclosures appear to be in line with industry norms and legal requirements.
• Unless new evidence emerges showing Capricor hid material negative facts already known to them before May 5, the basis for a successful securities class action seems weak.

What this really looks like:

A standard “stock drop” investigation announcement, often issued routinely after major biotech setbacks, without hard evidence of fraud at this time makes all these recent legal publications to be without merit. This means CAPR should be rounding up towards $34 - $77 dollars a share as the most recent financial analysts have pretty much all rated this stock a Strong Buy.

Here’s a refined side-by-side timeline analysis of Capricor’s public statements, FDA actions, and market reactions—from May 5, 2025, to July 2, 2025—with precise sourcing and context. This should offer a clearer picture of what truly unfolded and whether there’s substance behind the law firms’ claims.

 

📅 Timeline Breakdown

 

May 5, 2025 – Mid-Cycle Review Press Release

• Capricor: Announced successful mid-cycle meeting with the FDA, stating: FDA “confirmed its intent to hold an advisory committee meeting” and “no significant deficiencies” identified, with the BLA on track for an August 31 PDUFA date.
• FDA (via Reuters): Confirmed FDA plans to convene an advisory panel, triggering a drop in Capricor’s stock (~12–15%) to $10.11.
• Market Reaction: A noticeable dip in share price immediately after the release.

 

May 9, 2025 – Independent Reporting

• Third-Party: Clinical press (CGTLive) echoed the FDA’s intent to hold an advisory committee meeting, confirming Capricor’s summary. Still no mention of “efficacy and safety uncertainty” by FDA.

 

June 11, 2025 – Key Regulatory Updates

• Capricor: Announced that the FDA pre-license inspection concluded with no material deficiencies; AdComm meeting scheduled for July 30; late-cycle review to follow, PDUFA August 31.
• CureDuchenne, Nasdaq and others: Reaffirmed the FDA-advised advisory committee date of July 30.

 

June 20, 2025 – STAT Breaks the Suspension Story

• STAT: Reported that FDA’s CBER director (Vinay Prasad)—a new head—canceled the advisory meeting, citing concerns over the therapy’s efficacy and safety. We believe the law firms have a case against STAT for their erroneous practice of reporting something that hasn’t been confirmed.
• Capricor’s Stock: Dropped about $3.68 (≈30.8%), closing at $8.26.
• Note: This narrative came from STAT, not FDA’s official communication channels.

 

June 24, 2025 – Capricor Official Update

• Capricor: Official announcement:
  • FDA states “an Advisory Committee meeting is not indicated at this time.”
  • Late-cycle meeting scheduled for mid-July.
  • BLA remains under Priority Review for August 31 PDUFA.
• Reuters: Corroborated that FDA will not convene an external advisory panel.

 

🧠 Summary & Analysis

 

 

🔍 Did the FDA Officially Cite “Efficacy & Safety Uncertainty”?

• No, the FDA did not officially use that phrase.
• The notion of “efficacy and safety uncertainty” originates from only non-FDA publications as STAT’s reporting, not any public FDA release or Capricor communication.
• Capricor’s June 24 update never referenced efficacy/safety concerns—only procedural changes (“meeting not indicated”) ().

 

✅ Final Takeaway

• Capricor accurately reported FDA input on May 5 and June 24. Any legal reports of further Law Firms should be seriously taken with caution at this time. THEY DON’T HAVE MERIT WHATSOEVER TO DATE.
• They could bring suite or claim against actually STAT the originator of a non-substantiated claim(s) of something said that has never even been given support by any members of the FDA or ever appeared or appears within their full publications as referenced through any FDA document for anything that might assist in confirming such a statement when they made the statement back on June 20th, 2025 only blurted out without substantiation by STAT.
• The claim about many law firms that have gone fishing with sometimes nefarious angles we have seen and reported in articles in our past to take all those SHORTING CAPR and run CAPR up like when we witnessed Game Stop (GME) or TESLA (TSLA) to chase those who would dare to short them by options or just plain out borrowing CAPR shares and selling them than buying them back at a much lower share price, a share price to cause a company stocks to be short traded which the TRUTH IS AS FOLLOWS: canceled AdComm due to “efficacy and safety uncertainty” appears to be a secondary interpretation by STAT, not an FDA statement.
• Stock market drops reflect public updates and investor sentiment, not evidence of corporate fraud or misleading disclosures.
• Unless internal FDA documents surface, law firms’ assertions remain speculative without clear proof.

STAT is a well-known, independent media company focused exclusively on health, medicine, and life sciences news. Here’s their role and context in this Capricor story:

What Is STAT?

• STAT (statnews.com) is not a government agency, regulatory authority, or a participant in clinical trials.
• It is a journalistic outlet owned by Boston Globe Media Partners and widely respected for breaking news and investigative journalism in biotechnology, pharmaceuticals, and healthcare policy.
• Their readership includes medical professionals, investors, scientists, and biotech executives.

 

STAT’s Role in the Capricor Case

• STAT did not speak for the FDA or Capricor. Instead, it reported on developments in the Capricor–FDA BLA process based on their journalistic sources, which sometimes include unnamed FDA officials, industry insiders, or leaked internal communications.
• In this instance, STAT was the first to report (on June 20, 2025) that the new head of the FDA’s Center for Biologics Evaluation and Research (CBER), Dr. Vinay Prasad, had canceled the advisory committee meeting for Capricor’s Deramiocel.
• STAT claimed the cancellation was due to concerns over “efficacy and safety”—but this phrasing is STAT’s interpretation or reporting, not a direct FDA quote.
• After STAT’s report, other media and law firms referenced STAT’s article, amplifying the news and often treating the wording as if it were an official FDA stance, which it was not.

Why Does STAT Matter?

• STAT is highly influential—its scoops can move biotech stocks and trigger market and legal reactions.
• In this case, their reporting appears to be the sole source of the “efficacy and safety uncertainty” language now echoed by law firms.
• However, as a journalistic outlet, STAT’s language may reflect interviews, analysis, or anonymous sources—not formal regulatory statements.

 

Summary Table

Bottom line:

STAT is a media source, not a decision-maker. Their report set off the chain of events—but their language about “efficacy and safety uncertainty” is not the FDA’s official position. This distinction is critical for any legal or investment analysis.

Remember to keep CYDY on your radar. 

---

More By This Author:

CYDY: This Penny Stock Keeps Looking Better Coming Into Summer
Implications Of New FDA Leadership In The Biotechnology Industry
Building Wealth Through Economics: A Patriotic Investor’s Guide To Tariffs 2.0 And Why